Page last updated: 2024-12-06

tilomisole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tilomisole is a synthetic imidazole derivative that exhibits anthelmintic activity. It has been investigated for its potential to treat various parasitic infections, including those caused by nematodes and cestodes. Tilomisole is thought to act by inhibiting the synthesis of microtubules, which are essential components of the cytoskeleton in parasites. It has been shown to be effective against a range of parasitic species in experimental models, including *Haemonchus contortus* and *Dictyocaulus viviparus*, which are important parasites of livestock. Despite its promising activity, tilomisole has not been widely used in clinical practice due to the development of other more effective anthelmintics. Its synthesis involves a multi-step process starting from readily available starting materials. Researchers continue to study tilomisole and its derivatives for potential applications in veterinary medicine and as a starting point for the development of new antiparasitic drugs.'

tilomisole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID42747
CHEMBL ID2104737
SCHEMBL ID441312
MeSH IDM0093235

Synonyms (31)

Synonym
tilomisole
nsc-310633
wy-18251
58433-11-7
D06148
tilomisole (usan/inn)
2-[1-(4-chlorophenyl)-[1,3]thiazolo[3,2-a]benzimidazol-2-yl]acetic acid
CHEMBL2104737
651g60u372 ,
tilomisolum
wy-18,251
tilomisolum [latin]
3-(p-chlorophenyl)thiazolo(3,2-a)benzimidazole-2-acetic acid
tilomisol
thiazolo(3,2-a)benzimidazole-2-acetic acid, 3-(4-chlorophenyl)
tilomisol [spanish]
tilomisole [usan:inn]
unii-651g60u372
SCHEMBL441312
tilomisole [usan]
tilomisole [inn]
PUYFLGQZLHVTHX-UHFFFAOYSA-N
3-(p-chlorophenyl)-thiazolo[3,2-a]benzimidazole-2-acetic acid
3-(p-chlorophenyl)thiazol[3,2-a]benzimidazol-2-acetic acid
3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazol-2- acetic acid
DTXSID40207137
Q6587418
2-[1-(4-chlorophenyl)-[1,3]thiazolo[3,2-a]benzo[d]imidazol-2-yl]acetic acid
wy 18251
HY-106050
CS-0024734

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"The antimetastatic activity of a thiazolobenzimidazole, Wy-18,251 was investigated using various dosage regimens in mice with implanted Lewis lung tumors."( Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633).
Alburn, HE; Bloom, R; Fenichel, RL; Gregory, FJ; Schreck, PA, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1145284Antimetastatic activity against mouse LLC cells allografted in BDF1 mouse assessed as increase in host survival1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Syntheses of heterocylic fused thiazole acetic acids. 2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (76.92)18.7374
1990's2 (15.38)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.46 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]